An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach

Toxicology

Volumn 258, Issue 2-3, 2009, Pages 116-130

  Halleck, M ^a   Davis, H R ^a   Kirschmeier, P ^a   Levitan, D ^a   Snyder, R D ^a   Treinen, K ^a   MacDonald, J S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

1 (4 Fluorophenyl) 3(R) 3 (4 fluorophenyl) 3(S) hyroxypropyl 4(s) (4 hydroxyphenyl) 2 azetidinone; Carcinogenicity; Ezetimibe; Neimann Pick C1 Like 1 transporter

Indexed keywords

DNA; EZETIMIBE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARCINOGEN TESTING; CARCINOGENICITY; CELL MATURATION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; DATA BASE; EXPERIMENTAL DOG; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENOTOXICITY; KNOCKOUT MOUSE; LIVER; MALE; MICRONUCLEUS TEST; MOUSE; MUTAGEN TESTING; NONHUMAN; PRIORITY JOURNAL; RAT; TARGET ORGAN;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARCINOGENICITY TESTS; CARCINOGENS; DOGS; FEMALE; GENE EXPRESSION; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MUTAGENICITY TESTS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; MUS; RATTUS;

EID: 61349115459     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.01.017     Document Type: Article

References (57)

1. Alonso S.R., Tracey L., Ortiz P., Pérez-Gómez B., Palacios J., Pollán M., Serrano S., Sáez-Castillo A.I., Sánchez L., Pajares R., Sánchez-Aguilera A., Artiga M.J., Piris M.A., and Rodriques-Peralto J.L. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 67 (2007) 3450-3460
2. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J. Am. Coll. Cardiol. 50 (2007) 409-418
3. Alsheikh-Ali A.A., Trikalinos T.A., Kent D.M., and Karas R.H. Statins, low-density lipoprotein cholesterol, and risk of cancer. J. Am. Coll. Cardiol. 52 (2008) 1141-1147
4. Altmann S.W., Davis H.R., Zhu L., Yao X., Hoos L.M., Tetzloff G., Iyer S.P.N., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., and Graziano M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303 (2004) 1201-1204
5. Ames B.N., and Gold L.S. Chemical carcinogenesis: too many rodent carcinogens. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 7772-7776
6. Armitage P. Tests for linear trend in proportions and frequencies. Biometrics 11 (1955) 375-386
7. Batta A.K., Xu G., Bollineni J.S., Shefer S., and Salen G. Effect of high plant sterol-enriched diet and cholesterol absorption inhibitor, SCH 58235, on plant sterol absorption and plasma concentrations in hypercholesterolemic wild-type Kyoto rats. Metab. Clin. Exp. 54 (2005) 38-48
8. Boobis A.R., Cohen S.M., Dellarco V., McGregor D., Meek M.E., Vickers C., Willcocks D., and Farland W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 36 (2006) 781-792
9. Bradford P.G., and Awad A.B. Phytosterols as anticancer compounds. Mol. Nutr. Food Res. 51 (2007) 161-170
10. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278 [Errata, Lancet 366, 1358, 2005; Lancet 371, 2084].
11. Ciminera J.L. Some issues in the design, evaluation, and interpretation of tumorigenicity studies in animals. Proceedings of the Symposium on Long Term Animal Carcinogenicity Studies: A Statistical Perspective (1985), American Statistical Association, Washington, DC 26-35
12. Cohen S.M., and Ellwein L.B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51 (1991) 6493-6505
13. Cohen S.M. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol. Sci. 80 (2004) 225-229
14. Cutler S.J., and Ederer F. Maximum utilization of the life table method in analyzing survival. J. Chronic Dis. 8 (1958) 699-712
15. Davis H.R., Zhu L., Hoos L.M., Tetzloff G., Maguire M., Liu J., Yao X., Iyer S.P.N., Lam M., Lund E.G., Detmers P.A., Graziano M.P., and Altmann S.W. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279 32 (2004) 33586-33592
16. Davis H.R., Hoos L.M., Tetzloff G., Maguire M., Zhu L., Graziano M.P., and Altmann S.W. Deficiency of Niemann-Pick C1 Like 1 (NPC1L1) prevents atherosclerosis in apoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 841-849
17. Davis H.R., and Veltri E.P. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J. Atheroscler. Thromb. 14 (2007) 99-108
18. Davis H.R., Basso F., Hoos L.M., Tetzloff G., Lally S.M., and Altmann S.W. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 (NPC1L1). Atheroscler. Suppl. 9 (2008) 77-81
19. Drazen J.M., D'Agostino R.B., Ware J.H., Morrissey S., and Curfman G.D. Ezetimibe and cancer-an uncertain association. New Eng. J. Med. 359 (2008) 1398-1399
20. Dujovne C.A., Suresh R., McCrary-Sisk C., Maccubbin D., Strony J., and Veltri E. Safety and efficacy of ezetimibe monotherapy in 1624 primary hyperecholesterolemia patients for up to 2 years. Int. J. Clin. Pract. 62 (2008) 1332-1336
21. Fleming T.R. Identifying and addressing safety signal in clinical trials. New Eng. J. Med. 359 (2008) 1400-1402
22. Garcia-Calvo M., Lisnock J., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., Crona J.H., Davis H.R., Dean D.C., Detmers P.A., Graziano M.P., Hughes M., MacIntyre D.E., Ogawa A., O'Neill K.A., Iyer S.N., Shevell D.E., Smith M.M., Tang Y.S., Ujjainwalla F., Altmann S.W., Chapman K.T., and Thornberry N.A. The target of ezetimibe is Niemann-Pick C1 Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U.S.A. 102 23 (2005) 8132-8137
23. ®(SD)BR Rats Maintained on Dietary Restriction (1998), Charles River Laboratories
24. ®(ICR)BR Mouse (2000), Charles River Laboratories
25. Guidance for Industry. Statistical Aspects of the Design, Analysis and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals (Draft 2001) (2001), US. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research
26. Harter H.L. Error rates and sample sizes for range tests in multiple comparisons. Biometrics 13 (1957) 511-536
27. Hazan R.B., Qiao R., Keren R., Badano I., and Suyama K. Cadherin switch in tumor progression. Ann. N.Y. Acad. Sci. 1014 (2004) 155-163
28. Heyse J.F., and Rom D. Adjusting for multiplicity of statistical tests in the analysis of carcinogenicity studies. Biometr. J. 30 (1988) 883-896
29. Hill A.B. The environment and disease: association or causation?. Proc. R. Soc. Med. 58 (1965) 295-300
30. ICH S1B, 1997. International Conference on Harmonization ICH S1B. Guidance for Industry S1B: Testing for Carcinogenicity of Pharmaceuticals. http://www.ich.org/LOB/media/MEDIA490.pdf.
31. ICH S1C, 2008. International Conference on Harmonization ICH S1C. Guidance for Industry S1B: Dose Selection for Carcinogenicity Studies of Pharmaceuticals. http://www.ich.org/LOB/media/MEDIA491.pdf.
32. ICH S2B, 1997. International Conference on Harmonization S2B. Guidance for Industry on Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals. http://www.ich.org/LOB/media/MEDIA494.pdf.
33. Liu J., Campen A., Huang S., Peng S.B., Ye X., Palakal M., Dunker A.K., Xia Y., and Li S. Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data. BMC Med. Genomics 1 (2008) 39
34. MacDonald J.S., Lankas G.R., and Morrissey R.E. Toxicokinetic and mechanistic considerations in the interpretation of the rodent bioassay. Toxicol. Pathol. 22 (1994) 124-140
35. Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J. Am. Stat. Assoc. 58 (1963) 690-700
36. Matthews E.J., and Contrera J.F. A newly highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Reg. Toxicol. Pharmacol. 28 (1998) 242-264
37. Mattthews E.J., Kruhlak N.L., Cimino M.C., Benz R.D., and Contrera J.F. An analysis genetic toxicity, reproductive and developmental toxicity and carcinogenicity data: II. Indentification of genotoxicants, reprotoxicants and carcinogens using in silico methods. Reg. Toxicol. Pharmacol. 44 (2006) 97-110
38. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., and Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33 (2003) 591-653
39. Monni O., Franssila K., Joensuu H., and Knuutila S. BCL2 overexpression in diffuse large B-cell lymphoma. Leuk. Lymphoma 34 1-2 (1999) 45-52
40. Monro A.M., and MacDonald J.S. Evaluation of the carcinogenic potential of pharmaceuticals. Drug Safety 18 (1998) 309-319
41. O'Brien T.G., Simsiman R.C., and Boutwell R.K. Induction of the polyamine-biosynthetic enzymes in mouse epidermis and their specificity for tumor promotion. Cancer Res. 35 (1975) 2426-2433
42. Peto R., Pike M.C., Day N.E., Gray R.G., Lee P.N., Parish S., Peto J., Richards S., and Wahrendorf J. Guidelines for simple sensitive tests for carcinogenic effects in long-term animal experiments. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Supplement 2 (1980) 365-367
43. Peto R., Emberson J., Landray M., Baigent C., Collins R., Clare R., and Califf R. Analyses of cancer data from three ezetimibe trials. New Eng. J. Med. 359 (2008) 1357-1366
44. Pitot H.C., and Dragon Y.P. Chemical carcinogenesis. In: Klaassen C.D. (Ed). Casarett and Doull's Toxicology (2001), McGraw-Hill, New York 241-320
45. Robinson J.G., Davidson M.H., Shah A., Lin J., Neff D., DeLucca P.T., Tomassini J.E., Veltri E.P., and Tershakovec A.M. Efficacy and safety of ezetimibe and ezetimibe and statin therapy in patients aged < 65, 65-74, and 75 years and older. Aging Health 3 6 (2007) 691-705
46. Rossebø A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., Gerdts E., Gohlke-Bärwolf C., Holme I., Kesäniemi Y.A., Malbecq W., Nienaber C.A., Ray S., Skjaerpe T., Wachtell K., and Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. New Eng. J. Med. 359 (2008) 1343-1356
47. Sabbah M., Emami S., Redeuilh G., Julien S., Prévost G., Zimber A., Ouelaa R., Bracke M., De Wever O., and Gespach C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Update 11 (2008) 123-151
48. Seed J., Carney E.W., Corley R.A., Crofton K.M., DeSesso J.M., Foster P.M., Kavlock, Kimmel G., Klaunig J., Meek M.E., Preston R.J., Slikker W., Tabacova S., Williams G.M., Wiltse J., Zoeller R.T., Fenner-Crisp P., and Patton D.E. Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit. Rev. Toxicol. 35 (2005) 663-673
49. Snyder R.D., Pearl G.S., Mandakas G., Choy W.-N., Goodsaid F., and Rosenblum I.Y. Assessment of the sensitivity of the computational programs DEREK, TOPKAT and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ. Mol. Mutagen. 43 (2004) 143-158
50. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., and Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Reg. Toxicol. Pharmacol. 34 (2001) 146-152
51. Tarone R.E. The use of historical control information in testing for a trend in proportions. Biometrics 38 (1982) 215-220
52. Taylor A.J., and Nissen S.E. Preliminary observations from preliminary trial results. Have we finally had enough?. Circ. Cardiovasc. Qual. Outcomes 1 (2008) 54-57
53. Weingärtner O., Lütjohann D., Ji S., Weisshoff N., List F., Sudhop T., von Bergmann K., Gertz K., König J., Schäfers H.-J., Endres M., Böhm M., and Laufs U. Vascular effects of diet supplementation with plant sterols. J. Am. Coll. Cardiol. 51 (2008) 1553-1561
54. Weisburger J.H., and Williams G.M. Carcinogen testing: current problems and new approaches. Science 214 (1981) 401-407
55. Yamashita T., Forgues M., Wang W., Kim J.W., Ye Q., Jia H., Budhu A., Zanetti K.A., Chen Y., Qin L.X., Tang Z.Y., and Wang X.W. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68 5 (2008) 1451-1461
56. Yuspa S.H., Lichti U., Ben T., Patterson E., Hennings H., Slaga T.J., Colburn N., and Kelsey W. Phorbol esters stimulate DNA synthesis and ornithine decarboxylase activity in mouse epidermal cell cultures. Nature 262 5567 (1976) 402-404
57. Zheng S., Hoos L., Cook J., Tetzloff G., Davis Jr. H., van Heek M., and Hwa J.J. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur. J. Pharm. 584 (2008) 118-124